NYSE · PFE
Healthcare · Drug Manufacturers - General
$28.28
Up+$0.46 (+1.65%)
Updated Oct 10, 2026, 8:42 PM
SID Score
7.5/10
Composite research score
Smart Money
65/100
Neutral
Price performance · PFE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
PFE closed at $28.28 after 21 trading sessions, up 2.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $27.61 | $28.285 | $27.59 | $28.28 | 23.2M |
| Oct 8, 2026 | $27.90 | $28.00 | $27.475 | $27.82 | 44.43M |
| Oct 7, 2026 | $27.62 | $28.17 | $27.55 | $28.00 | 31.23M |
| Oct 6, 2026 | $27.48 | $27.71 | $27.20 | $27.50 | 24.07M |
| Oct 5, 2026 | $27.65 | $27.72 | $27.12 | $27.41 | 33.01M |
| Oct 2, 2026 | $28.145 | $28.16 | $27.44 | $27.80 | 35.01M |
| Oct 1, 2026 | $28.445 | $28.585 | $28.075 | $28.12 | 30.49M |
| Sep 30, 2026 | $28.79 | $28.945 | $28.52 | $28.52 | 33.64M |
| Sep 29, 2026 | $28.60 | $28.76 | $28.26 | $28.72 | 33.31M |
| Sep 28, 2026 | $28.62 | $28.87 | $28.39 | $28.72 | 24.95M |
| Sep 25, 2026 | $28.45 | $28.69 | $28.17 | $28.67 | 27.76M |
| Sep 24, 2026 | $28.20 | $28.85 | $28.20 | $28.41 | 34.77M |
| Sep 23, 2026 | $27.96 | $28.23 | $27.84 | $28.18 | 33.81M |
| Sep 22, 2026 | $27.74 | $28.00 | $27.49 | $27.93 | 26.67M |
| Sep 21, 2026 | $27.65 | $27.92 | $27.53 | $27.74 | 28.78M |
| Sep 18, 2026 | $27.64 | $27.66 | $27.34 | $27.66 | 75.59M |
| Sep 17, 2026 | $27.62 | $27.81 | $27.55 | $27.64 | 29.01M |
| Sep 16, 2026 | $27.64 | $27.69 | $27.36 | $27.46 | 26.05M |
| Sep 15, 2026 | $27.615 | $27.66 | $27.245 | $27.55 | 40.44M |
| Sep 14, 2026 | $28.08 | $28.19 | $27.685 | $27.72 | 28.57M |
| Sep 11, 2026 | $27.80 | $27.85 | $27.42 | $27.72 | 25.56M |
The latest Smart Investors Daily articles mentioning PFE.
Company
Market Activity
Research & News
PFE research
Company profile and research snapshot.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Neutral | — |
| Oct 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Oct 6, 2026 | Scotiabank | Sector Outperform | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
Generated Oct 10, 2026, 5:11 PM
Pfizer shares gained 1.65% today as positive pharmaceutical pipeline developments offset a broader neutral market sentiment. The modest rally reflects investor optimism around recent drug approvals and valuation opportunities, even as the company's growth trajectory remains under scrutiny.
Bottom line: Pfizer's modest gains today reflect a cautiously optimistic view of its drug pipeline, particularly the TUKYSA maintenance approval, paired with attractive dividend metrics for income investors. However, investors should remain aware that the company's valuation discount hasn't yet translated into robust revenue growth, and competitive dynamics in biotech remain a headwind worth monitoring.
Yahoo · Oct 10, 2026
A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using a blended yield of about 7.4% based on trailing distributions and early October 2026 prices, you’d need roughly $1.99 million to generate the […]
Yahoo · Oct 9, 2026
Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.
Yahoo · Oct 9, 2026
Pfizer Inc. (NYSE:PFE) is up 11.4% year-to-date and leads to a classic value-versus-risk setup. The stock’s forward price-to-earnings multiple appears attractive, along with its healthy operating margin, and strong cash flow generation capacity. However, revenue growth remains sluggish, and the company’s thin bottom-line margin and low return on equity add to investor concerns. It explains […]
Yahoo · Oct 9, 2026
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PFE.
